| Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis D Drygin, A Siddiqui-Jain, S O'Brien, M Schwaebe, A Lin, J Bliesath, ... Cancer research 69 (19), 7653-7661, 2009 | 632 | 2009 |
| Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth D Drygin, A Lin, J Bliesath, CB Ho, SE O'Brien, C Proffitt, M Omori, ... Cancer research 71 (4), 1418-1430, 2011 | 612 | 2011 |
| CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy A Siddiqui-Jain, D Drygin, N Streiner, P Chua, F Pierre, SE O'Brien, ... Cancer research 70 (24), 10288-10298, 2010 | 543 | 2010 |
| Discovery and SAR of 5-(3-Chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic Acid (CX-4945), the First Clinical Stage Inhibitor of Protein Kinase CK2 for … F Pierre, PC Chua, SE O’Brien, A Siddiqui-Jain, P Bourbon, M Haddach, ... Journal of medicinal chemistry 54 (2), 635-654, 2011 | 326 | 2011 |
| Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer R Battistutta, G Cozza, F Pierre, E Papinutto, G Lolli, S Sarno, SE O’Brien, ... Biochemistry 50 (39), 8478-8488, 2011 | 176 | 2011 |
| Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer F Pierre, PC Chua, SE O’Brien, A Siddiqui-Jain, P Bourbon, M Haddach, ... Molecular and cellular biochemistry 356 (1), 37-43, 2011 | 160 | 2011 |
| Quantum molecular similarity. Part 2: The relation between properties in BCP space and bond length SE O'Brien, PLA Popelier Canadian journal of chemistry 77 (1), 28-36, 1999 | 156 | 1999 |
| Greater than the sum of its parts: combining models for useful ADMET prediction SE O'Brien, MJ de Groot Journal of medicinal chemistry 48 (4), 1287-1291, 2005 | 151 | 2005 |
| Discovery of CX-5461, the first direct and selective inhibitor of RNA polymerase I, for cancer therapeutics M Haddach, MK Schwaebe, J Michaux, J Nagasawa, SE O'Brien, ... ACS medicinal chemistry letters 3 (7), 602-606, 2012 | 149 | 2012 |
| Quantum molecular similarity. 3. QTMS descriptors SE O'Brie, PLA Popelier Journal of Chemical Information and Computer Sciences 41 (3), 764-775, 2001 | 127 | 2001 |
| CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy A Siddiqui-Jain, J Bliesath, D Macalino, M Omori, N Huser, N Streiner, ... Molecular cancer therapeutics 11 (4), 994-1005, 2012 | 125 | 2012 |
| Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma JR Devlin, KM Hannan, N Hein, C Cullinane, E Kusnadi, PY Ng, ... Cancer discovery 6 (1), 59-70, 2016 | 123 | 2016 |
| Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells J Bliesath, N Huser, M Omori, D Bunag, C Proffitt, N Streiner, C Ho, ... Cancer letters 322 (1), 113-118, 2012 | 93 | 2012 |
| Chemical modelling: applications and theory PLA Popelier, FM Aicken, SE O’Brien Royal Society of Chemistry Specialist Periodical Report 1, 143-198, 2000 | 93* | 2000 |
| Discovery of CX-6258. A potent, selective, and orally efficacious pan-Pim kinases inhibitor M Haddach, J Michaux, MK Schwaebe, F Pierre, SE O’Brien, C Borsan, ... ACS medicinal chemistry letters 3 (2), 135-139, 2012 | 92 | 2012 |
| Antitumor benzothiazoles. Frontier molecular orbital analysis predicts bioactivation of 2-(4-aminophenyl) benzothiazoles to reactive intermediates by cytochrome P4501A1 SE O'Brien, HL Browne, TD Bradshaw, AD Westwell, MFG Stevens, ... Organic & biomolecular chemistry 1 (3), 493-497, 2003 | 86 | 2003 |
| Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer D Drygin, CB Ho, M Omori, J Bliesath, C Proffitt, R Rice, A Siddiqui-Jain, ... Biochemical and biophysical research communications 415 (1), 163-167, 2011 | 76 | 2011 |
| Quantum topological molecular similarity. Part 4. A QSAR study of cell growth inhibitory properties of substituted (E)-1-phenylbut-1-en-3-ones SE O'Brien, PLA Popelier Journal of the Chemical Society, Perkin Transactions 2, 478-483, 2002 | 71 | 2002 |
| RNA Polymerase I Inhibition with CX‐5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma HC Lee, H Wang, V Baladandayuthapani, H Lin, J He, RJ Jones, I Kuiatse, ... British journal of haematology 177 (1), 80-94, 2017 | 70 | 2017 |
| Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells S Zanin, C Borgo, C Girardi, SE O'Brien, Y Miyata, LA Pinna, ... PLoS One 7 (11), e49193, 2012 | 69 | 2012 |
